
[ Mon, May 16th 2022 ]: WOPRAI
[ Mon, May 16th 2022 ]: WOPRAI
[ Mon, May 16th 2022 ]: WOPRAI
[ Mon, May 16th 2022 ]: WOPRAI
[ Mon, May 16th 2022 ]: WOPRAI
[ Mon, May 16th 2022 ]: WOPRAI
[ Mon, May 16th 2022 ]: WOPRAI
[ Mon, May 16th 2022 ]: WOPRAI
[ Mon, May 16th 2022 ]: WOPRAI
[ Mon, May 16th 2022 ]: WOPRAI
[ Mon, May 16th 2022 ]: WOPRAI
[ Mon, May 16th 2022 ]: WOPRAI
[ Mon, May 16th 2022 ]: WOPRAI
[ Mon, May 16th 2022 ]: WOPRAI
[ Mon, May 16th 2022 ]: WOPRAI
[ Mon, May 16th 2022 ]: WOPRAI
[ Mon, May 16th 2022 ]: WOPRAI
[ Mon, May 16th 2022 ]: WOPRAI
[ Mon, May 16th 2022 ]: WOPRAI
[ Mon, May 16th 2022 ]: WOPRAI
[ Mon, May 16th 2022 ]: WOPRAI
[ Mon, May 16th 2022 ]: WOPRAI
[ Mon, May 16th 2022 ]: WOPRAI
[ Mon, May 16th 2022 ]: WOPRAI
[ Mon, May 16th 2022 ]: WOPRAI
[ Mon, May 16th 2022 ]: WOPRAI
[ Mon, May 16th 2022 ]: WOPRAI
[ Mon, May 16th 2022 ]: WOPRAI
[ Mon, May 16th 2022 ]: WOPRAI
[ Mon, May 16th 2022 ]: WOPRAI
[ Mon, May 16th 2022 ]: WOPRAI
[ Mon, May 16th 2022 ]: WOPRAI
[ Mon, May 16th 2022 ]: WOPRAI
[ Mon, May 16th 2022 ]: WOPRAI
[ Mon, May 16th 2022 ]: WOPRAI
[ Mon, May 16th 2022 ]: WOPRAI
[ Mon, May 16th 2022 ]: WOPRAI
[ Mon, May 16th 2022 ]: WOPRAI
[ Mon, May 16th 2022 ]: WOPRAI
[ Mon, May 16th 2022 ]: WOPRAI
[ Mon, May 16th 2022 ]: WOPRAI
[ Mon, May 16th 2022 ]: WOPRAI
[ Mon, May 16th 2022 ]: WOPRAI
[ Mon, May 16th 2022 ]: WOPRAI
[ Mon, May 16th 2022 ]: WOPRAI
[ Mon, May 16th 2022 ]: WOPRAI
[ Mon, May 16th 2022 ]: WOPRAI
[ Mon, May 16th 2022 ]: WOPRAI
David Westenberg Maintained (AKYA) at Buy with Decreased Target to $14 on, May 16th, 2022


🞛 This publication is a summary or evaluation of another publication
David Westenberg of Piper Sandler, Maintained "Akoya Biosciences, Inc." (AKYA) at Buy with Decreased Target from $18 to $14 on, May 16th, 2022.
David has made no other calls on AKYA in the last 4 months.
There is 1 other peer that has a rating on AKYA. Out of the 1 peers that are also analyzing AKYA, 0 agree with David's Rating of Hold.
This is the rating of the analyst that currently disagrees with David
- Tejas Savant of "Morgan Stanley" Maintained at Buy with Decreased Target to $18 on, Monday, May 9th, 2022